MR Imaging Characteristics Associate with Tumor-Associated Macrophages in Glioblastoma and Provide an Improved Signature for Survival Prognostication

References

1. 1.↵
   2. Stupp R,
   3. Mason WP,
   4. van den Bent MJ, et al

   . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96 doi:10.1056/NEJMoa043330 pmid:15758009

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Pickett HA,
   3. Reddel RR

   . Molecular mechanisms of activity and derepression of alternative lengthening of telomeres. Nat Struct Mol Biol 2015;22:875–80 doi:10.1038/nsmb.3106 pmid:26581522

   CrossRefPubMed
3. 3.↵
   2. Hakin-Smith V,
   3. Jellinek DA,
   4. Levy D, et al

   . Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet 2003;361:836–38 doi:10.1016/S0140-6736(03)12681-5 pmid:12642053

   CrossRefPubMedWeb of Science
4. 4.↵
   2. Hung NA,
   3. Eiholzer RA,
   4. Kirs S, et al

   . Telomere profiles and tumor-associated macrophages with different immune signatures affect prognosis in glioblastoma. Mod Pathol 2016;29:212–26 doi:10.1038/modpathol.2015.156 pmid:26769142

   CrossRefPubMed
5. 5.↵
   2. Wu CX,
   3. Lin GS,
   4. Lin ZX, et al

   . Peritumoral edema on magnetic resonance imaging predicts a poor clinical outcome in malignant glioma. Oncol Lett 2015;10:2769–76 doi:10.3892/ol.2015.3639 pmid:26722240

   CrossRefPubMed
6. 6.↵
   2. Pope WB,
   3. Sayre J,
   4. Perlina A, et al

   . MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol 2005;26:2466–74 pmid:16286386

   Abstract/FREE Full Text
7. 7.↵
   2. Li WB,
   3. Tang K,
   4. Chen Q, et al

   . MRI manifestions correlate with survival of glioblastoma multiforme patients. Cancer Biol Med 2012;9:120–23 doi:10.3969/j.issn.2095-3941.2012.02.007 pmid:23691466

   CrossRefPubMed
8. 8.↵
   2. Schoenegger K,
   3. Oberndorfer S,
   4. Wuschitz B, et al

   . Peritumoral edema on MRI at initial diagnosis: an independent prognostic factor for glioblastoma? Eur J Neurol 2009;16:874–78 doi:10.1111/j.1468-1331.2009.02613.x pmid:19473360

   CrossRefPubMed
9. 9.↵
   2. Maldaun MV,
   3. Suki D,
   4. Lang FF, et al

   . Cystic glioblastoma multiforme: survival outcomes in 22 cases. J Neurosurg 2004;100:61–67 doi:10.3171/jns.2004.100.1.0061 pmid:14743913

   CrossRefPubMed
10. 10.↵
    2. Utsuki S,
    3. Oka H,
    4. Suzuki S, et al

    . Pathological and clinical features of cystic and noncystic glioblastomas. Brain Tumor Pathol 2006;23:29–34 doi:10.1007/s10014-006-0195-8 pmid:18095116

    CrossRefPubMedWeb of Science
11. 11.↵
    2. Hammoud MA,
    3. Sawaya R,
    4. Shi W, et al

    . Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol 1996;27:65–73 doi:10.1007/BF00146086 pmid:8699228

    CrossRefPubMed
12. 12.↵
    2. Kaur G,
    3. Bloch O,
    4. Jian BJ, et al

    . A critical evaluation of cystic features in primary glioblastoma as a prognostic factor for survival. J Neurosurg 2011;115:754–59 doi:10.3171/2011.5.JNS11128 pmid:21761969

    CrossRefPubMed
13. 13.↵
    2. Carrillo JA,
    3. Lai A,
    4. Nghiemphu PL, et al

    . Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. AJNR Am J Neuroradiol 2012;33:1349–55 doi:10.3174/ajnr.A2950 pmid:22322613

    Abstract/FREE Full Text
14. 14.↵
    2. Pierallini A,
    3. Bonamini M,
    4. Osti MF, et al

    . Supratentorial glioblastoma: neuroradiological findings and survival after surgery and radiotherapy. Neuroradiology 1996;38 Suppl 1:S26–30 doi:10.1007/s002340050913 pmid:8811675

    CrossRefPubMed
15. 15.↵
    2. Drabycz S,
    3. Roldán G,
    4. de Robles P, et al

    . An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging. Neuroimage 2010;49:1398–405 doi:10.1016/j.neuroimage.2009.09.049 pmid:19796694

    CrossRefPubMed
16. 16.↵
    2. Qi S,
    3. Yu L,
    4. Li H, et al

    . Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms. Oncol Lett 2014;7:1895–902 doi:10.3892/ol.2014.2013 pmid:24932255

    CrossRefPubMed
17. 17.↵
    2. Liu XY,
    3. Gerges N,
    4. Korshunov A, et al

    . Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 2012;124:615–25 doi:10.1007/s00401-012-1031-3 pmid:22886134

    CrossRefPubMedWeb of Science
18. 18.↵
    2. Gutman DA,
    3. Dunn WD Jr.,
    4. Grossmann P, et al

    . Somatic mutations associated with MRI-derived volumetric features in glioblastoma. Neuroradiology 2015;57:1227–37 doi:10.1007/s00234-015-1576-7 pmid:26337765

    CrossRefPubMed
19. 19.↵
    2. Aghi M,
    3. Gaviani P,
    4. Henson JW, et al

    . Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma. Clin Cancer Res 2005;11:8600–05 doi:10.1158/1078-0432.CCR-05-0713 pmid:16361543

    CrossRefPubMedWeb of Science
20. 20.↵
    2. Gutman DA,
    3. Cooper LA,
    4. Hwang SN, et al

    . MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. Radiology 2013;267:560–69 doi:10.1148/radiol.13120118 pmid:23392431

    CrossRefPubMedWeb of Science
21. 21.↵
    2. Hegi ME,
    3. Diserens AC,
    4. Gorlia T, et al

    . MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997–1003 doi:10.1056/NEJMoa043331 pmid:15758010

    CrossRefPubMedWeb of Science
22. 22.↵
    2. Hartmann M,
    3. Jansen O,
    4. Egelhof T, et al

    . Effect of brain edema on the recurrence pattern of malignant gliomas [Article in German]. Radiologe 1998;38:948–53 doi:10.1007/s001170050447 pmid:9861656

    CrossRefPubMed
23. 23.↵
    2. Rios Velazquez E,
    3. Meier R,
    4. Dunn WD Jr.., et al

    . Fully automatic GBM segmentation in the TCGA-GBM dataset: prognosis and correlation with VASARI features. Sci Rep 2015;5:16822 doi:10.1038/srep16822 pmid:26576732

    CrossRefPubMed
24. 24.↵
    2. Gevaert O,
    3. Mitchell LA,
    4. Achrol AS, et al

    . Glioblastoma multiforme: exploratory radiogenomic analysis by using quantitative image features. Radiology 2014;273:168–74 doi:10.1148/radiol.14131731 pmid:24827998

    CrossRefPubMedWeb of Science
25. 25.↵
    2. Henson JD,
    3. Hannay JA,
    4. McCarthy SW, et al

    . A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res 2005;11:217–25 pmid:15671549

    Abstract/FREE Full Text
26. 26.↵
    2. Capper D,
    3. Weissert S,
    4. Balss J, et al

    . Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 2010;20:245–54 doi:10.1111/j.1750-3639.2009.00352.x pmid:19903171

    CrossRefPubMedWeb of Science
27. 27.↵
    2. Royds JA,
    3. Pilbrow AP,
    4. Ahn A, et al

    . The rs11515 polymorphism is more frequent and associated with aggressive breast tumors with increased ANRIL and decreased p16 (INK4a) expression. Front Oncol 2015;5:306 doi:10.3389/fonc.2015.00306 pmid:26835415

    CrossRefPubMed
28. 28.↵
    2. Palmisano WA,
    3. Divine KK,
    4. Saccomanno G, et al

    . Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000;60:5954–58 pmid:11085511

    Abstract/FREE Full Text
29. 29.↵
    2. McDonald KL,
    3. McDonnell J,
    4. Muntoni A, et al

    . Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival. J Neuropathol Exp Neurol 2010;69:729–36 doi:10.1097/NEN.0b013e3181e576cf pmid:20535033

    CrossRefPubMed
30. 30.↵
    2. Ludwig HC,
    3. Feiz-Erfan I,
    4. Bockermann V, et al

    . Expression of nitric oxide synthase isozymes (NOS I-III) by immunohistochemistry and DNA in situ hybridization. Correlation with macrophage presence, vascular endothelial growth factor (VEGF) and oedema volumetric data in 220 glioblastomas. Anticancer Res 2000;20:299–304 pmid:10769671

    PubMed
31. 31.↵
    2. Senger DR,
    3. Galli SJ,
    4. Dvorak AM, et al

    . Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983–85 doi:10.1126/science.6823562 pmid:6823562

    Abstract/FREE Full Text
32. 32.↵
    2. Carlson MR,
    3. Pope WB,
    4. Horvath S, et al

    . Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2. Clin Cancer Res 2007;13:2592–98 doi:10.1158/1078-0432.CCR-06-2772 pmid:17473188

    Abstract/FREE Full Text
33. 33.↵
    2. Qiu XX,
    3. Wang CH,
    4. Lin ZX, et al

    . Correlation of high delta-like ligand 4 expression with peritumoral brain edema and its prediction of poor prognosis in patients with primary high-grade gliomas. J Neurosurg 2015;123:1578–85 doi:10.3171/2014.12.JNS14768 pmid:26047413

    CrossRefPubMed
34. 34.↵
    2. Jain RK,
    3. Tong RT,
    4. Munn LL

    . Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 2007;67:2729–35 doi:10.1158/0008-5472.CAN-06-4102 pmid:17363594

    Abstract/FREE Full Text
35. 35.↵
    2. Pierpaoli C,
    3. Jezzard P,
    4. Basser PJ, et al

    . Diffusion tensor MR imaging of the human brain. Radiology 1996;201:637–48 doi:10.1148/radiology.201.3.8939209 pmid:8939209

    CrossRefPubMedWeb of Science
36. 36.↵
    2. Mantovani A,
    3. Marchesi F,
    4. Malesci A, et al

    . Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 2017;14:399–416 doi:10.1038/nrclinonc.2016.217 pmid:28117416

    CrossRefPubMed
37. 37.↵
    2. Royds JA,
    3. Al Nadaf S,
    4. Wiles AK, et al

    . The CDKN2A G500 allele is more frequent in GBM patients with no defined telomere maintenance mechanism tumors and is associated with poorer survival. PloS One 2011;6:e26737 doi:10.1371/journal.pone.0026737 pmid:22046342

    CrossRefPubMed
38. 38.↵
    2. Chen YJ,
    3. Hakin-Smith V,
    4. Teo M, et al

    . Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma. Cancer Res 2006;66:6473–76 doi:10.1158/0008-5472.CAN-06-0910 pmid:16818615

    Abstract/FREE Full Text
39. 39.↵
    2. Metellus P,
    3. Coulibaly B,
    4. Colin C, et al

    . Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 2010;120:719–29 doi:10.1007/s00401-010-0777-8 pmid:21080178

    CrossRefPubMedWeb of Science
40. 40.↵
    2. Wang YY,
    3. Wang K,
    4. Li SW, et al

    . Patterns of tumor contrast enhancement predict the prognosis of anaplastic gliomas with IDH1 mutation. AJNR Am J Neuroradiol 2015;36:2023–29 doi:10.3174/ajnr.A4407 pmid:26316565

    Abstract/FREE Full Text